Containing insulin

CN code 300431 covers medicines containing insulin, put up in measured doses or in forms for retail sale. Insulin is a peptide hormone produced by the pancreas, essential for regulating blood glucose levels. Products classified under this code include ready-to-use insulin medicines in ampoule form, pen cartridges (insulin pens), multi-dose vials, and infusion systems for insulin pumps. This encompasses recombinant human insulin, insulin analogues (rapid-acting: lispro, aspart, glulisine; long-acting: glargine, detemir, degludec) and premixed insulins. Classification under code 300431 requires that the product is prepared for direct patient administration and packaged in retail doses. Insulin in the form of a bulk active substance, not prepared in doses, is classified under heading 2937 as a peptide hormone.

Insulin medicines imported into the EU must hold a marketing authorisation (MA) issued through the centralised EMA procedure or a national procedure by the competent regulatory authority. Most modern insulin analogues are subject to the mandatory centralised procedure as biological medicines. The manufacturer must hold a GMP certificate compliant with Directive 2003/94/EC, and insulin production is subject to specific requirements for biological product manufacturing, including validation of biotechnological processes. The Falsified Medicines Directive 2011/62/EU requires serialisation of insulin medicine packaging with a unique DataMatrix identifier and anti-tampering device. Insulin transport must maintain the cold chain (2 to 8 degrees Celsius) in accordance with GDP principles. The pharmacoepidemiological system requires maintaining adverse reaction registries and implementing Risk Management Plans (RMPs).

Customs clearance of insulin medicines under CN code 300431 requires presentation of the marketing authorisation, manufacturer's GMP certificate, Batch Release Certificate issued by an OMCL, Certificate of Analysis (CoA), and documentation confirming cold chain maintenance during transport. Insulin is a thermolabile product - even brief deviations from the 2 to 8 degrees Celsius range can cause protein degradation and loss of biological activity, leading to batch rejection. Duty rates for insulin medicines should be verified in TARIC or ISZTAR. Many insulin medicines benefit from autonomous duty suspensions or tariff preferences under EU trade agreements. Given the critical importance of insulin for diabetes patients, customs authorities typically prioritise clearance of these products; however, the importer should notify the customs office of planned imports in advance.

Importing pharmaceutical products under CN code 3004 31 (Medicines containing insulin) requires authorisation from the national medicines agency. All medicines placed on the EU market must hold a marketing authorisation issued by EMA (centralised procedure) or a national authority. Compliance with Good Manufacturing Practice (GMP) confirmed by a certificate is mandatory. Biological products require cold chain maintenance. Serialisation and authenticity verification (FMD 2011/62/EU) are mandatory for prescription medicines.